Transcriptomic profiling in Malawian patients with acute hypersensitivity reactions to Nevirapine

Nevirapine is a non-nucleoside reverse transcriptase inhibitor, a class of antiretroviral drug, used for the treatment of HIV-1 infection. Despite its wide use, nevirapine treatment has been associated with a significant incidence of different kind of hypersensitivity reactions (HSRs). We used microarrays to find significant genes that can relate to Nevirapine-persuaded hypersensitivity reactions in ‘acute’ patients compared to ‘recovered’ and/or ‘tolerant’ patients. We have selected 18 patients’ samples, 6 from each group (Acute, Recovered, Tolerant) to investigate Nevirapine induced hypersensitivity reactions using transcriptomic profiling based on microarray technology. Acute:Patient taking nevirapine develops adverse drug reaction (ADR). Recovered: 6 weeks after acute reaction-not longer taking nevirapine. Tolerant: Patient on neviraoine and tolerating treatment.

奈韦拉平（Nevirapine）属于非核苷类逆转录酶抑制剂（non-nucleoside reverse transcriptase inhibitor），是一类抗逆转录病毒药物，用于HIV-1感染的治疗。尽管该药物应用广泛，但奈韦拉平治疗常伴随较高发生率的各类超敏反应（hypersensitivity reactions, HSRs）。本研究采用微阵列（microarrays）技术，旨在筛选出相较于“康复”及/或“耐受”患者，与“急性”奈韦拉平诱导超敏反应相关的差异基因。我们共纳入18例患者样本，每组（急性组、康复组、耐受组）各6例，通过基于微阵列技术的转录组谱分析（transcriptomic profiling），探究奈韦拉平诱导的超敏反应。其中：急性组指服用奈韦拉平后出现药物不良反应（adverse drug reaction, ADR）的患者；康复组指急性反应发生6周后且已停用奈韦拉平的患者；耐受组指持续服用奈韦拉平且耐受治疗的患者。